Effect of Diabetes Control on Outcome in Hospitalized Patients: A National Israeli Study
NCT ID: NCT00813475
Last Updated: 2008-12-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
200 participants
INTERVENTIONAL
2009-01-31
2011-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients admitted to internal medicine departments in public hospitals of Israel who have pre-admission diagnosis of diabetes, or have a random plasma glucose \>200 mg/dl on admission
Eligibility criteria
1. Age: \>18 years
2. Fasting plasma glucose \> 140 mg/dl or non-fasting plasma glucose \>200 mg/dl in two separate blood tests if non-diabetic, or in a single blood test if have pre-diagnosed diabetes
3. Able to understand the study objective and methods and willing to provide a written informed consent
4. No significant liver disease
5. Serum creatinine \<2.0 mg/dl
Exclusion criteria
1. Significant cognitive impairment
2. History of hypoglycemia unawareness or clinical autonomic diabetic neuropathy
3. Known allergy to insulin analogues
4. Diabetic ketoacidosis or non-ketotic hyperosmolar coma on admission
Process of patient recruitment and randomization:
1. Enrolment of eligible patients signing the informed consent.
2. Assignment of patients to different treatment arms according to randomization scheme provided by the central organizing committee.
3. The ratio of patients' assignment to the active or to the control study arm will be 1:1 for each participating ward.
Protocol:
Basal bolus insulin treatment will be applied to achieve tight glucose target (mean fasting blood glucose\<130 mg/dl and not above 180 mg/dl during the day) compared to patients treated to achieve less tight glucose targets (mean fasting blood glucose\<200 mg/dl and not above 220 mg/dl during the day)will influence cardiovascular and general clinical outcome.
Primary outcome: All-cause mortality (including in-hospital and up to 12 months post discharge) or re-admission to hospital
Secondary outcomes:
Total number of in-hospital days during one year follow-up (including the index hospital admission)
The rate of any major clinical events (all-cause mortality, hospital acquired infection, organ failure, need of ventilation support, need of vasoactive amine administration, need of central line insertion, hospital admission for stroke, acute coronary event, severe bacterial or fungal infection) during one year follow-up
Hypoglycemic events during index hospital stay.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
tight control
Basal bolus insulin regimen (tight glucose control)
Basal bolus insulin regimen
standard control
basal bolus insulin regimen
Basal bolus insulin regimen (standard control)
basal bolus insulin regimen
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Basal bolus insulin regimen (tight glucose control)
Basal bolus insulin regimen
Basal bolus insulin regimen (standard control)
basal bolus insulin regimen
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Fasting plasma glucose \> 140 mg/dl or non-fasting plasma glucose \>200 mg/dl in two separate blood tests if non-diabetic, or in a single blood test if have pre-diagnosed diabetes
3. Able to understand the study objective and methods and willing to provide a written informed consent
4. No significant liver disease
5. Serum creatinine \<2.0 mg/dl
\-
Exclusion Criteria
2. History of hypoglycemia unawareness or clinical autonomic diabetic neuropathy
3. Known allergy to insulin analogues
4. Diabetic ketoacidosis or non-ketotic hyperosmolar coma on admission
\-
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assaf-Harofeh Medical Center
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Assaf-Harofeh Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assaf Harofeh Medical Center
Ẕerifin, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
184-08
Identifier Type: -
Identifier Source: org_study_id